COMPANY PROFILE

Histogenics

Tissue regeneration company developing breakthrough treatments for long-lasting joint repair

Waltham, United StatesFounded 2000Biotech & Life Sciences

Valuation $294M Market cap · 2012

About Histogenics

Histogenics, operating under the name Ocugen, Inc., is a biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies aimed at curing blindness diseases. The company focuses on retinal disorders, including Dry Age-Related Macular Degeneration and Inherited Retinal Disorders such as Retinitis Pigmentosa. Ocugen's innovative gene therapy platform has the potential to treat multiple retinal diseases with a single drug, offering a significant advantage over existing treatments. The company's novel biologic product candidates are designed to provide better therapeutic options for patients suffering from underserved diseases like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Ocugen serves a global market, targeting patients with rare and underserved eye conditions. The business model revolves around the development and commercialization of its proprietary therapies, generating revenue through product sales, partnerships, and licensing agreements.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2000
Headquarters: Waltham, United States
Listing: IPO 2014
Employees: 10
Open positions: None listed
Dealroom signal: 27.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Investment activity: 1 company, latest May 2011
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITYOther financing	Oct 2018	$17M	—	Undisclosed	↗
POST IPO EQUITYOther financing	Oct 2016	$30M	—	Split Rock Partners · Sofinnova Investments	—

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Histogenics website traffic

Latest recorded traffic for Histogenics is 0 monthly website visits. Histogenics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%

Monthly website visitsApr 2016–Aug 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CYCytosolixAcidity-targeted small molecule oncology drug derivatives	New Haven, United States	Operational	4	$7M	$27M
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
GRGRIPWISEDigital dynamometer and platform for muscular strength assessment.	Braga, Portugal	Operational
KBKither BiotechDevelopment of new products for targeted therapies, in particular to fight airway disease and targeting PI3Ks with safety \| Academic spin-off of the University of Turin	Turin, Italy	Operational
FIFitbiomicsFitbiomics utilizes next-generation sequencing to understand what makes elite athletes unique	New York City, United States	Operational
CACamallergyOral immunotherapy treatments for food and peanut allergies	Cambridge, United Kingdom	Operational
QKQkineHigh-purity, animal-free proteins for life science applications	Cambridge, United Kingdom	Operational
FLFlomicsRNA liquid biopsy for early multi-cancer detection	Barcelona, Spain	Operational